LigoCyte Pharmaceuticals, Inc.

Although norovirus currently has no approved drug therapy and is implicated in an estimated 200,000 deaths globally each year, competition in this space is limited to four clinical candidates, Datamon

Takeda Pharmaceutical Co. Ltd. has begun dosing in an international Phase III clinical program with its candidate prophylactic vaccine for dengue, TAK-003, closing the gap on the only commercialized

The first dosing in a new Phase IIb, placebo-controlled trial with Takeda Pharmaceutical Co. Ltd. 's bivalent vaccine for norovirus marks the first large-scale study anywhere for a candidate to pro

Takeda Pharmaceutical Co. Ltd. is implementing a major restructuring of its global vaccine business unit (VBU), which will involve the closure of three sites in the U.S. that came to the company fro